# A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

> **NCT01870843** · PHASE4 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 261 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT01870843
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870843, "A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01870843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*